Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06800261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of PCV24 in Infants Aged 2-23 Months

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 2025 to Jun 2026
    • Study sites: 1 to 2
    • Start date changed from estimate of Apr 2025 to May 8, 2025
    v3
  2. Start date: Feb 2025 to Apr 2025
    • Primary completion date: Jan 2026 to Sep 2025
    • Eligibility criteria expanded, about 9 words
    • Study site revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.
Trial Details
NCT Number NCT06800261
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions
(from sponsor)		 Pneumococcal Infectious Disease
Related terms Pneumococcal Infections
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov